ACAD · ACADIA Pharmaceuticals Inc.
$24.84
+2.44% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$4B
Trailing P/E
11.5
Forward P/E
29.7
Dividend yield
—
Beta
0.80
Avg volume
2M
Employees
1K
2D change
—
5D change
2.26%
10D change
-0.82%
30D change
0.28%
60D change
17.22%
MTD change
0.75%
YTD change
-4.94%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ACAD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-21
Latest call per bank · past 12 months
RBC Capital
Outperform$36.00
+44.9% vs priceBank of America
Buy$30.00
+20.8% vs priceCitigroup
Buy$35.00
+40.9% vs priceJP Morgan
Overweight$34.00
+36.9% vs priceUBS
Buy$40.00
+61.0% vs priceGoldman Sachs
Sell$17.00
-31.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | BMO Capital | Maintains | Outperform | $34.00 → $36.00 |
| 2026-07-21 | Stifel | Maintains | Hold | $24.00 → $25.00 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $29.00 → $36.00 |
| 2026-06-30 | Bank of America | Maintains | Buy | $29.00 → $30.00 |
| 2026-06-29 | Citigroup | Maintains | Buy | $32.00 → $35.00 |
| 2026-06-29 | Canaccord Genuity | Maintains | Buy | $32.00 → $36.00 |
| 2026-05-08 | Citigroup | Maintains | Buy | $33.00 → $32.00 |
| 2026-05-07 | Canaccord Genuity | Maintains | Buy | $33.00 → $32.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.8% above the 50-day MA ($23.26).
- Price vs 200-day MA: Trading 10.5% above the 200-day MA ($23.53).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.16) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($20.06) and high ($28.06).
ACAD Price Chart
Loading chart for ACAD…
Fundamentals
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.